Deep Brain Stimulation Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):– https://datamintelligence.com/download-sample/deep-brain-stimulation-market?an

The global Deep Brain Stimulation Market reached US$ 800.12 million in 2023 and is expected to reach US$ 1,585.24 million by 2031 growing with a CAGR of 9.1% during the forecast period 2024-2031.

List of the Key Players in the  Deep Brain Stimulation Market:

Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Aleva Neurotherapeutics, NeuroPace, Inc., SceneRay Co., Ltd., PINS Medical, Renishaw plc., BrainsWay Ltd., inomed Medizintechnik GmbH and among others.

Industry Development:

In April 2024, Medtronic India introduced the NeuroSmart™ Portable Micro Electrode Recording (MER) Navigation System for Deep Brain Stimulation (DBS) in Parkinson’s disease treatment. Developed by Alpha Omega Engineering, this advanced system enhances neurophysiological navigation, ensuring precise electrode placement and real-time neural activity recording. Featuring HaGuide automatic navigation, it optimizes target localization, maximizing symptom relief for patients.

In August 2024, Medtronic plc became the first and only company to receive U.S. FDA approval for Asleep Deep Brain Stimulation (DBS) surgery, allowing patients with Parkinson’s disease and essential tremors to undergo DBS under general anesthesia instead of traditional awake procedures.

In September 2024, Abbott launched a pivotal clinical trial to evaluate its Deep Brain Stimulation (DBS) therapy for treatment-resistant depression. Abbott has previously gained approvals for brain neuromodulation systems targeting movement disorders like Parkinson’s disease and essential tremor, as well as spinal cord implants designed to manage chronic pain. These DBS devices deliver small electrical pulses to stimulate brain tissue, functioning similarly to a pacemaker.

Growth Forecast Projected:

The Global  Deep Brain Stimulation Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Deep Brain Stimulation Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the  Deep Brain Stimulation Market:

By Product Type: Single-Channel Systems, Dual-Channel Systems

By Battery Type: Rechargeable Systems, Non-Rechargeable Systems

By Stimulation Type: Constant Current Devices, Voltage-Controlled Devices

By Application: Movement Disorders, Parkinson's Disease, Dystonia, Essential Tremor, Others, Psychiatric Disorders, Obsessive-Compulsive Disorder (OCD), Depression, Others, Epilepsy, Chronic Pain, Alzheimer's Disease, Tourette Syndrome, Others

By End-User: Hospitals and Clinics, Neurological Centers, Ambulatory Surgical Centers, Others

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com 
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com